Release Date: 23 January 2025
UBB-2048 is an investigational bispecific antibody developed by Unity Biotechnology, designed to address retinal vascular diseases by targeting two critical components involved in pathological blood vessel formation. It i...
Release Date: 23 January 2025
HX009 is a promising first-in-class humanized bispecific antibody fusion protein developed by Waterstone Hanxbio. This innovative therapy is designed to target two key components of the immune system: the PD-1 checkpoint ...
Release Date: 23 January 2025
Vudalimab, developed by Xencor, is an innovative bispecific antibody that targets two key immune checkpoint receptors, PD-1 and CTLA-4. These receptors play critical roles in regulating immune responses, and their inhibit...
Release Date: 23 January 2025
QLF 31907 is an innovative bispecific antibody developed by Qilu Pharmaceutical, designed to target two critical components of the immune checkpoint pathway: PD-L1 and 4-1BB (also known as CD137). This antibody is being i...
Release Date: 23 January 2025
PRV-3279 (also known as MGD 010) is a monoclonal antibody being developed by Provention Bio, a subsidiary of Sanofi, under a license from MacroGenics. It is designed for the treatment of autoimmune disorders, with a prima...
Release Date: 23 January 2025
CKD702 is an innovative tetravalent, bispecific antibody developed by Chong Kun Dang Pharmaceutical with potential antineoplastic activity. This antibody is designed to target two critical cell surface receptors involved ...
Release Date: 23 January 2025
BAT-7104 is a promising next-generation bispecific monoclonal antibody developed by Biothera. This innovative drug candidate targets both the PD-1/PD-L1 and CD47/SIRP-andalpha; immune checkpoint pathways, which play signi...
Release Date: 23 January 2025
IBI323 is an innovative LAG-3/PD-L1 bispecific antibody being developed by Innovent Biologics, designed to enhance immune system activity against tumors. This bispecific antibody targets two crucial immune checkpointsandm...
Release Date: 23 January 2025
6MW3211 is a promising humanized bispecific antibody developed by Mabwell (Shanghai) Bioscience, with a focus on cancer immunotherapy. This innovative treatment is designed to target two key immune checkpoints, PD-L1 and ...
Release Date: 23 January 2025
Navicixizumab (OMP 305B83) is an innovative bispecific antibody designed to target two critical pathways involved in tumor growth and angiogenesis. Developed by Mereo Biopharma and OncXerna Therapeutics, this antibody tar...
Release Date: 23 January 2025
Plamotamab (formerly known as XmAb 13676) is a bispecific antibody developed by Xencor, designed to target two key antigens involved in the immune response against hematological malignancies. It is currently being investi...
Release Date: 23 January 2025
Fazpilodemab (formerly known as BFKB8488A) is an innovative bispecific antibody developed by Genentech, designed to target fibroblast growth factor receptor 1 (FGFR1) and klotho beta protein (KLB). This antibody holds pro...
Release Date: 23 January 2025
IBI318 is an innovative first-in-class bispecific antibody developed to target both PD-1 and PD-L1, two key components of the immune checkpoint pathway. This recombinant immunoglobulin G1 (IgG1) bispecific antibody is des...
Release Date: 23 January 2025
KP104, developed by Kira Pharma, is a groundbreaking biologic that stands at the forefront of complement therapy. This first-in-class, bifunctional molecule is designed to target and block two key pathways in the compleme...
Release Date: 23 January 2025
PM8001 is a novel bifunctional fusion protein developed to target both programmed cell death ligand 1 (PD-L1) and transforming growth factor-beta (TGF-andbeta;), two critical players in the immune regulation of tumors. TG...